Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

Inclusion Criteria: * Healthy male and/or female subjects with suitable veins for cannulation or repeated venepuncture. * Males must be willing to use appropriate contraception methods. * Females must not be lactating and must be of non-childbearing potential, confirmed at Screening. * Have a body mass index between 18.5 and 30 kg/m\^2 (inclusive) and weigh at least 50 kg and no more than 100 kg (inclusive) at Screening. Exclusion Criteria: * History of any clinically significant disease or disorder. * History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * A positive Corona Virus Disease 2019 test at Screening or admission to the Clinical Unit on Day -1. * Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results. * Any clinically significant abnormal findings in vital signs. * clinically significant abnormalities on 12-lead electrocardiogram. * Any positive result at the Screening Visit for Hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus antibody. * Known or suspected history of drug abuse in the last 2 years. * Current smokers or those who have smoked or used nicotine products within the 3 months prior to the Screening Visit. * Known or suspected history of alcohol or drug abuse. * Use of any prescribed or non-prescribed medication. * Subjects with acute pulmonary insufficiency, marked neuromuscular respiratory weakness, obsessional states, phobic states, sleep apnoea syndrome, or unstable myasthenia gravis. * History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigatoror history of hypersensitivity to drugs with a similar chemical structure or class to AZD4831 or midazolam. * History or ongoing allergy/hypersensitivity to drugs(including but not limited to rash, angioedema, acute urticaria). * Subjects who, in the opinion of the Investigator, have any clinically significant skin condition.